Regeneron Pharmaceuticals (LTS:0R2M) Inventories, Other: $821 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0R2M Regeneron Pharmaceuticals Inc LTS:0R2M
91 GF Score
Price $796.46
GF Value $905.91
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Regeneron Pharmaceuticals Inventories, Other?

Regeneron Pharmaceuticals LTS:0R2M +1.73% 91 Inventories, Other is $821 Mil as of Jun. 2026. GuruFocus rates LTS:0R2M with a GF Score™ of 91/100 and a GF Value™ of $905.91 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Regeneron Pharmaceuticals's other inventories for the quarter that ended in Jun. 2026 was $821 Mil.

Regeneron Pharmaceuticals's quarterly other inventories increased from Dec. 2025 ($728 Mil) to Mar. 2026 ($788 Mil) and increased from Mar. 2026 ($788 Mil) to Jun. 2026 ($821 Mil).

Regeneron Pharmaceuticals's annual other inventories increased from Dec. 2023 ($522 Mil) to Dec. 2024 ($726 Mil) and increased from Dec. 2024 ($726 Mil) to Dec. 2025 ($728 Mil).

Regeneron Pharmaceuticals Inventories, Other Historical Data

* Premium members only.

The historical data trend for Regeneron Pharmaceuticals's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regeneron Pharmaceuticals Inventories, Other Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Other
Get a 7-Day Free Trial Premium Member Only Premium Member Only 448.50 521.80 522.10 725.70 727.50

Regeneron Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Inventories, Other Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 764.40 808.80 727.50 787.90 820.90
LTS:0R2M
91GF Score
Regeneron Pharmaceuticals Inc LTS:0R2M
Inventories, Other is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Regeneron Pharmaceuticals Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.

Frequently Asked Questions Learn more about Inventories, Other →
What does a Inventories, Other of $821 Mil mean?
Regeneron Pharmaceuticals (LTS:0R2M) has a Inventories, Other of $821 Mil as of Jun. 2026. Other inventories a company records on its balance sheet, like goods for resale and stocks in transit. View historical data on Regeneron Pharmaceuticals and its competitors.
Is Regeneron Pharmaceuticals' Inventories, Other too high?
Regeneron Pharmaceuticals' current Inventories, Other is $821 Mil. Overall, Regeneron Pharmaceuticals has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Regeneron Pharmaceuticals' Inventories, Other compare to MRNA and RVMD?
Regeneron Pharmaceuticals' Inventories, Other of $821 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Other for a Biotechnology company?
A good Inventories, Other depends on the Biotechnology industry context. However, Inventories, Other should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Other mean?
A high Inventories, Other can signal that a stock is expensive relative to its fundamentals. Other inventories a company records on its balance sheet, like goods for resale and stocks in transit. View historical data on Regeneron Pharmaceuticals and its competitors. Regeneron Pharmaceuticals's current Inventories, Other is $821 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regeneron Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals (LTS:0R2M) is currently considered Modestly Undervalued. The stock's GF Value™ is $905.91, compared to a current price of $796.46 — trading 12.1% below its estimated fair value. The current Inventories, Other is $821 Mil. Regeneron Pharmaceuticals' overall GF Score™ is 91/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Other calculated?
Inventories, Other is calculated from a company's financial statements. For Regeneron Pharmaceuticals (LTS:0R2M), the current Inventories, Other is $821 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Regeneron Pharmaceuticals (LTS:0R2M) Overvalued in 2026?

Based on GuruFocus' analysis, Regeneron Pharmaceuticals stock appears to be undervalued. The current stock price of $796.46 is trading 12.1% below its estimated GF Value™ of $905.91. GuruFocus considers Regeneron Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for LTS:0R2M:

  • Inventories, Other: $821 Mil
  • GF Value™: $905.91 vs. price of $796.46 (12.1% below fair value)
  • GF Score™: 91/100 with 6 warning signs

No single metric tells the full story. See the LTS:0R2M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Regeneron Pharmaceuticals Business Description

Address 777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
91GF Score

Get the complete analysis for LTS:0R2M

Inventories, Other is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$796.46
Price
$905.91
GF Value